<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01061060</url>
  </required_header>
  <id_info>
    <org_study_id>BER-CL-AKR-2009-01</org_study_id>
    <nct_id>NCT01061060</nct_id>
  </id_info>
  <brief_title>The Effect of Prostaglandin I2 on the Endothelial Cell Function Disorder in Type 2 Diabetes Mellitus Patients</brief_title>
  <official_title>The Effect of Prostaglandin I2 (Beraprost Na), Administered Orally for Eight Weeks, on the Endothelial Cell Functional Disorder in Type II Diabetes Mellitus Patients With Symptoms of a Minute Peripheral Blood Flow Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Korea, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study attempts to examine the effect of oral prostaglandin I2 (Beraprost Na),
      administered for eight weeks, on the endothelial cell functional disorder among asymptomatic
      high risk diabetes mellitus patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study plans to include those subjects who have complaint of peripheral microvascular
      symptoms but have evidences of having neither a coronary arterial disease nor a peripheral
      arterial disease and show normal findings in the vascular stiffness test (PWV and ABI)) and
      plethysmography of the legs (PVR)) ,among Type II diabetes mellitus patients of forty-five
      (45) years old or older, This study is conducted by using a randomized double blind method.
      These drugs are distributed through a pharmacy in the clinical study center and administered
      randomly for eight weeks while this study allots patients by using a double blind method.
      Beraprost Na is administered along with a placebo that was manufactured by the same
      manufacturer to have the identical exterior look and weight of Beraprost Na. After eight
      weeks of drug administration, this investigation attempts to verify symptomatic improvement
      and change in the endothelial function by using VENDYSÂ® and ICG perfusion imaging.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptomatic improvement by Total Symptom Score (TSS)</measure>
    <time_frame>after 8-week treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in endothelial function expressed in the unit of temperature rebound and the extent of its rise</measure>
    <time_frame>after 8-week treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean rate of blood flow in the toes</measure>
    <time_frame>after 8-week treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Peripheral Microvascular Symptoms</condition>
  <arm_group>
    <arm_group_label>Beraprost group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prostaglandin I2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prostaglandin I2</intervention_name>
    <description>oral</description>
    <arm_group_label>Beraprost group</arm_group_label>
    <other_name>Beraprost Na</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type II diabetes mellitus patient

          -  Patients with symptoms of a minute peripheral blood flow disorder

        Exclusion Criteria:

          -  Cases with either an already-diagnosed coronary arterial disease or a peripheral
             vascular disease

          -  Cases with a history of stroke

          -  Cases with an abnormal finding of vascular stiffness test (PWV and ABI) and
             plethysmography of legs (PVR)

          -  Pregnant women or fertile women with an unclear pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Professor Dong-Hoon Choi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal Medicine, Severance Hospital, Yonsei Medical School, Yonsei University</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <state>Seodaemun-gu</state>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2010</study_first_submitted>
  <study_first_submitted_qc>February 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2010</study_first_posted>
  <last_update_submitted>February 11, 2016</last_update_submitted>
  <last_update_submitted_qc>February 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yonsei University</investigator_affiliation>
    <investigator_full_name>Donghoon Choi</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Prostaglandin I2</keyword>
  <keyword>Beraprost Na</keyword>
  <keyword>Endothelial cell function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Beraprost</mesh_term>
    <mesh_term>Epoprostenol</mesh_term>
    <mesh_term>Tezosentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

